drugset / Trial / NCT05056974
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo ART interruption.
Timeline
- Start
- 2021-12-02
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEMZUVOLIMAB | Protein / enzyme biologic | 10 mg/kg | — |
| Subject | Tucidinostat | Small molecule | 10 mg | — |